Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.
Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.
Burke
Michael J
MJ
Division of Hematology/Oncology/Transplant, Children's Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Cohn
Susan L
SL
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000310:Adrenal Gland Neoplasms / Q000150:complications* / Q000601:surgery; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D002653:Child Behavior Disorders / Q000209:etiology; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003951:Diagnostic Errors; D018305:Ganglioneuroblastoma / Q000150:complications* / Q000601:surgery; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007167:Immunotherapy; D007859:Learning Disabilities / Q000209:etiology; D008297:Male; D053578:Opsoclonus-Myoclonus Syndrome / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000628:therapy; D011596:Psychomotor Disorders / Q000209:etiology; D012008:Recurrence; D000069283:Rituximab
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D000069283:Rituximab